Products

Mocetinostat 726169-73-9

1.Inquiries will be replied within 24 hours
2.We could supply various packages as you required
3.To protect the profit of our agents, price will not show on website, please send inquiries to get the price.
4.Fast delivery, goods arrive your office within 3 to 5 days
5.Please click "Inquiry" or "Email" below to get the price
 
Synonyms
Appearance
white powder
Chemical Formula
C23H20N6O
Solubility
Molecular Weight
396.44
Storage and Stability
in stock
CAS No.
726169-73-9
Purity
99.5%
Introduction
Mocetinostat is a potent isotype-selective HDAC inhibitor with IC50 of 0.15, 0.29, 1.66 and 0.59 μM for HDAC1HDAC2,HDAC3 and HDAC11, respectively. IC50 & Target: IC50: 0.15 μM (HDAC1), 0.29 μM (HDAC2), 1.66 μM (HDAC3), 0.59 μM (HDAC11) In Vitro: Mocetinostat (MGCD0103) exhibits potent and selective antiproliferative activities against a broad spectrum of human cancer cell lines in vitro, and HDAC inhibitory activity is required for these effects. In all cell lines tested, Mocetinostat (MGCD0103) partially inhibits cellular HDAC enzyme activity although the maximal inhibition of activity varies among cell lines from 75% to 85% of total activity. The IC50 of Mocetinostat in intact cancer cells is independent of tissue origin. In A549 cells, MGCD0103 shows dose-dependent inhibition of HDAC activity in whole cells. At high concentrations in A549 cells, Mocetinostat inhibits a maximum of 80% of total activity. In HCT116 cells, Mocetinostat induces a significant S-phase depletion and both G1 and G2-M accumulationIn Vivo:Mocetinostat (MGCD0103) significantly inhibits growth of human tumor xenografts in nude mice in a dose-dependent manner and the antitumor activity correlated with induction of histone acetylation in tumors. The p.o. administration of Mocetinostat (MGCD0103) (2HBr salt) significantly reduces growth of implanted advanced A549 tumors in nude mice in a dose-dependent manner after 13 days of daily administration. Mocetinostat (170 mg/kg for 2HBr salt, corresponding to 120 mg/kg of free base) significantly blocks growth of tumors compared with vehicle treatment alone (P<0.05 in post-ANOVA Dunnett's test) with no change in body weight.

Thank you for your company product support!

CAS No. :

Product Name :

Number :

Your name:
*

Phone:

Email:
*

The company or laboratory name:
*